Attention:

Certain features of Sigma-Aldrich.com will be down for maintenance the evening of Friday August 18th starting at 8:00 pm CDT until Saturday August 19th at 12:01 pm CDT.   Please note that you still have telephone and email access to our local offices. We apologize for any inconvenience.

Nuclear Receptors (Steroids)

Intracellular receptors (IRs) are a class of ligand-dependent transcription factors that include receptors for both steroid and non-steroid hormones. Upon binding their cognate hormone, these receptors homo- or hetero-dimerize and regulate gene expression through multiple mechanisms. Ligand-bound IRs can positively regulate transcription after binding to sequences within promoters containing binding sites for that IR; negative regulation can occur by direct binding to a promoter or indirectly by binding to and altering the activity of another transcription factor. It is now clear that accessory coactivator and corepressor proteins interact directly or indirectly with IRs play a key role in transcriptional regulation. These proteins, associate with the IR and influence chromatin organization and/or recruitment of basal transcription factors and RNA polymerase II. The pattern of genes modulated within a cell in response to an IR Ligand determines the ultimate effects on cell proliferation, cell differentiation and general cellular homeostasis.

Steroid receptors include receptors for glucocorticoids, progestins, estrogens, androgens and mineralocorticoids. While these receptors were demonstrated to exist within cells as early as the 1960s, it was not until 1984 that the first IR, the rat glucocorticoid receptor, was cloned and characterized. Since that time, the genes for all known human steroid IRs have been cloned.

Glucocorticoids are secreted from the adrenal cortex in response to adrenocorticotropic hormone (ACTH). Glucocorticoids are primarily responsible for regulating carbohydrate, lipid and protein metabolism, cardiovascular function and the immune system. In response to stress, the levels of endogenous corticosteroids can rise ten-fold. Therapeutically, synthetic corticosteroids including prednisone and dexamethasone are primarily used for their anti-inflammatory and immunoregulatory effects to treat both acute inflammatory responses, such as asthma, as well as chronic inflammatory diseases, such as rheumatoid arthritis. They are also used in various cancer chemotherapeutic regimens as a palliative treatment and for certain lymphoid malignancies because of their ability to induce apoptosis in specific immune cells.

Aldosterone, the major mineralocorticoid, is secreted from the adrenal gland and possibly other tissues. Aldosterone functions to maintain water and electrolyte balance by acting upon the distal tubules and collecting ducts of the kidney. Aldosterone antagonists, such as spironolactone, are potassium-sparing diuretics used for the treatment of hypertension. Spironolactone also shows significant benefit in the treatment of congestive heart failure.

Progesterone and other progestins are secreted by the corpus luteum during the menstrual cycle and play a key role in the early maintenance of the endometrial lining during pregnancy. Progestins, alone or in combination with estrogens, are used as oral contraceptives. Progestin antagonists, such as mifepristone (RU 486), can be used early in pregnancy as abortifacients.

Estrogens are synthesized by the ovaries in premenopausal women. Estrogens function to maintain secondary sexual characteristics and bone integrity in women. After menopause, estrogen replacement reduces hot flashes and prevents significant bone loss. The estrogen receptor partial agonist, tamoxifen, is widely used in treating breast cancer. The partial agonist raloxifene is also an antagonist in the breast and an agonist for bone, but lacks the uterotrophic activity of tamoxifen. The molecular basis for these differences upon selective cofactor recruitment by ER bound to these selective ER modulators. In addition, aromatase inhibitors, which prevent the conversion of androgens to estrogen (e.g. anastrozole, letrozole, and exemestane) are also used to treat ER-positive breast cancer.

Testosterone, dihydrotestosterone and other androgens are responsible for behavioral and secondary sexual characteristics of both males and females. Testosterone, synthesized de novo by the testes and adrenal gland, is secreted during gestation, again during the neonatal period, and throughout adulthood. Testosterone functions to support sexual differentiation, spermatogenesis and has significant anabolic effects on muscle and bone. Antagonists of testosterone are used to treat prostate cancer. Inhibitors of the conversion of testosterone to dihydrotestosterone have been used to treat benign prostatic hypertrophy and may reverse male pattern baldness.

 

The Table below contains accepted modulators and additional information. For a list of additional products, see the "Similar Products" section below.

 

Currently Accepted Name

Estrogen receptor
Glucocorticoid receptor
Alternate Name ERα (NR3A1)
ERβ (NR3A2)
GR (NR3C1)
GRαa
Structural Information 595 aa (human) 777 aa (human)
Receptor Selective Agonists 17-β-Estradiol (E8875)
Estrone (E9750)
Moxestrol
Dexamethasone (D1756)
Triamcinolone (T6376)
Hydrocortisone (H4001)
Prednisone (P6254)
Receptor Selective Antagonists ICI 182,780 (I4409)
Keoxifene (R1402)
4-Hydroxytamoxifenb (H7904, H6278)
Tamoxifen (T5648, T9262)
Mifepristone (RU 486)c (M8046)
Onapristone (ZK 98299)c
ZK 91587
Signal Transduction Mechanisms Modulation of gene expression by ligand-dependent transcription factors
Radioligands of Choice [3H]-Estradiol
[125I]-Iodoestradiol
[3H]-Tamoxifen
[3H]-Hydroxycortisone
[3H]-Deoxycorticosterone
[3H]-Dexamethasone
Tissue Expression Ovary
Pituitary
Uterus
Ubiquitous
Physiological Function Maintenance of female reproductive system Regulation of carbohydrate, lipid, and protein metabolism
Regulation of cardiovascular and immune function
Disease Relevance Osteoporosis
Cancer
Pregnancy prevention
Asthma
Arthritis
Cancer

 

 

Currently Accepted Name Progesterone receptor Androgen receptor Mineralocorticoid receptor
Alternate Name PRβ (NR3C3)
PRαd
AR (NR3C4) MR (NR3C2)
Structural Information 933 aa (human) 919 aa (human) 984 aa (human)
Receptor Selective Agonists Progesterone (P0130)
Norethynodrel
Medroxyprogesterone (M1629)
R5020
Iodovinylnortestosterone
Testosterone (T1500)
Stanolone (A8380)
Oxymetholone (O0380)
Oxandrolone (SML0437)
Methyltrienolone (R0908)
Fluoxymesterone
Androstenedione
Aldosterone (A9477)
Receptor Selective Antagonists Mifepristone (RU 486) (M8046)c
Onapristone (ZK 98299)c
Bicalutamide (B9061)
2-Hydroxyflutamide (H4166)e
Nilutamide (N8534)
Cyproterone acetate (C3412)f
Spironolactone (S3378)
Eplerenone (E6657)
Signal Transduction Mechanisms Modulation of gene expression by ligand-dependent transcription factors
Radioligands of Choice [125I]-Iodovinylnortestosterone
[3H]-Progesterone
[3H]-R5020
[3H]-Dihydrotestosterone
[3H]-Methyltrienolone
[3H]-Testosterone
[3H]-Aldosterone
[3H]-Spironolactone
Tissue Expression Uterus, brain, hypothalmus, ovary, spinal cord Adrenal, brain, epididymus, hypothalamus, kidney, muscle, ovary, pituitary, prostate, skin, uterus, adipose tissue Brain, colon, kidney, pituitary, skin, spinal cord, thyroid, heart
Physiological Function Establishment and maintenance of pregnancy
Breast development
Sexual behavior
Proper development and function of male reproductive organs
Anabolic action
Regulation of electrolyte and fluid balance
Specific CNS roles
Disease Relevance Pregnancy prevention and termination Prostate cancer
Osteoporosis
Frailty
Congestive heart failure
Blood pressure

 

Footnotes

a) A second GR isoform (GRβ) has been identified. GRβ contains 742 amino acids, does not bind glucocorticoids and has been shown to be a dominant-negative mutant.

b) Tissue-specific antagonist.

c) Potent antiglucocorticoid and antiprogestin with weaker potency as an antagonist on the androgen receptor.

d) PRα and PRβ are identical except for alternate splicing of amino terminal. PRβ is approximately 22 kDa larger. The pharmacological differences are not fully understood.

e) Active metabolite of flutamide.

f) Also a progesterone agonist.

 

Abbreviations

ICI 182,780: 7α-[9-(4,4,5,5,5-Pentafluoro-pentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17β-diol
R5020: 17,21-Dimethyl-19-nor-4,9-pregnadiene-3,20-dione

 

Similar Products


     

References